Inhibitory effect of troglitazone on glucuronidation catalyzed by human uridine diphosphate-glucuronosyltransferase 1A6

European Journal of Clinical Pharmacology

Volumn 56, Issue 12, 2001, Pages 893-895

  Ito, Masaki ^a   Yamamoto, Kazuo ^a   Sato, Hiroshi ^a   Fujiyama, Yoshihide ^a   Bamba, Tadao ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Inhibition; Troglitazone; UDP glucuronosyltransferase

Indexed keywords

1 NAPHTHOL; 1-NAPHTHOL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; GLUCURONOSYLTRANSFERASE; NAPHTHOL DERIVATIVE; THIAZOLE DERIVATIVE; TROGLITAZONE;

ARTICLE; DRUG ANTAGONISM; HUMAN; METABOLISM;

CHROMANS; GLUCURONOSYLTRANSFERASE; HUMANS; HYPOGLYCEMIC AGENTS; NAPHTHOLS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0035292718     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000252     Document Type: Article

References (14)

1. Strassburg CP, Oldhafer K, Manns MP, Tukey RH (1997) Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52: 212-220
2. Sato H. Adachi Y, Koiwai O (1996) The genetic basis of Gilbert's syndrome. Lancet 347: 557-558
3. Maruo Y. Nishizawa K, Sato H. Doida Y, Shimada M (1999) Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics 103: 1224-1227
4. Yamamoto K. Sato H, Fujiyama Y. Doida Y, Bamba T (1998) Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta 1406: 267-273
5. Ciotti M, Marrone A, Potter C. Owens IS (1997) Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 7: 485-495
6. Kohlroser J, Mathai J. Reichheld J, Banner BF, Bonkovsky HL (2000) Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95: 272-276
7. Fukano M, Amano S, Sato J, Yamamoto K, Adachi H, Okabe H, Fujiyama Y, Bamba T (2000) Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Hum Pathol 31: 250-253
8. Young MA, Lettis S, Eastmond R (1998) Coadministration of acetaminophen and troglitazone: pharmacokinetics and safety. J Clin Pharmacol 38: 819-824
9. Bock KW, Forster A, Gschaidmeier H, Bruck M, Munzel P. Schareck W. Fournel-Gigleux S, Burchell B (1993) Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases. Biochem Pharmacol 45: 18091814
10. Harding D, Fournel-Gigleux S, Jackson MR, Burchell B (1988) Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells. Proc Natl Acad Sci USA 85: 8381-8385
11. Lowry OH, Rosebrough NJ, Farr AL, Landall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275
12. 14C]glucuronic acid. Anal Biochem 109: 321-329
13. Loi CM, Randinitis EJ. Vassos AB, Kazierad DJ, Koup JR. Sedman AJ (1997) Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J Clin Pharmacol 37: 1114-1120
14. Kawai K, Kawasaki-Tokui Y, Odaka T. Tsuruta F, Kazui M. Iwabuchi H, Nakamura T, Kinoshita T, Ikeda T. Yoshioka T. Komai T, Nakamura K (1997) Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 47: 356-368